Specialty Injectable Generics Market - Global Forecast to 2026, by Product Type (Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

  • Published On : Mar 2019 |
  • Pages : 238 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Specialty Injectable Generics Market – A Cost Effective Approach in Chronic Diseases Treatment

Specialty injectable generics play a major role in advanced healthcare as they are used in treatment of various complex, life-threatening diseases such as cancer, cardiovascular diseases, HIV, hemophilia, rheumatoid arthritis, auto immune disorders, and others.

The global specialty injectable generics market size was valued at US$ 31,300 million in 2017, and is expected to exhibit a CAGR of 10.4 % over the forecast period (2018 – 2026).

Figure 1. Global Specialty Injectable Generics Value (US$ Mn), by Region, 2017

Specialty Injectable Generics  | Coherent Market Insights

                                                                Source: Coherent Market Insights Analysis (2019)

Increasing incidences of chronic diseases is expected to propel growth of the global specialty injectable generics market

Specialty injectable generics are used in treatment of complex disease condition such as cancer, hemophilia, HIV, Central Nervous System (CNS)-associated disorders, and others. High prevalence of cancer is expected to drive the market growth. According to World Health Organization (WHO), in 2012, cancer was the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. In 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to increase by around 70% by 2030.

Furthermore, increasing incidences of HIV/AIDS is propelling growth of the specialty injectable generics market over the forecast period. According to WHO, around 36.9 billion people were diagnosed with HIV in 2017, with nearly 1 in every 25 adults in Africa living with HIV.

However, expensive and complex process to manufacture the biologics and generic injectables. Not all manufacturers can invest and sustain such investment especially in the ever increasing competition in the specialty injectables generics market.

The FDA implemented CGMP guidelines for manufacturing of generic sterile injectables. Moreover, these generic drugs are priced at reduced rates than that of the branded drugs leading to significantly low profit margins for manufacturers. Moreover, the FDA has enhanced efforts to enforce GMP on manufacturers and hence, they are unable to capitalize on generic drugs. This is expected to be factor hampering growth of the global specialty injectables generics market.

 Figure 2. Global Specialty Injectable Generics Market Share (%), by Product Type, 2018 and 2026

Specialty Injectable Generics  | Coherent Market Insights

                                                                      Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of neurological disorders in North America is expected to bolster the market growth

North America holds dominant position in the specialty injectable generics market, owing to high prevalence of genetic disorders. According to the U.S. Pharmacist Journal, January 2018, around 1.2 million adults are diagnosed with early symptoms of brain disorders, annually, of which 21% are due to Alzheimer’s disease and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in the U.S.

Moreover, North America is the largest generics drug and biosimilar market worldwide especially in segments of specialty disease and large annual generic/biosimilar prescription. According to report by the U.S. Department of Commerce’s International Trade Administration in 2016, U.S. generic drug sales reached an estimated US$ 70 billion, which is a quarter of the global market. This was due to a large number of drugs going off-patent and healthcare reforms favoring generics. Generics holds 22% of total prescription sales and its share in filled prescriptions increased from 19% in 1984 to 88% in 2015.

Moreover, key players in the market are focused on receiving approval for generic products to enhance their product portfolio. For instance, in September 2017, Samsung Bioepis’ Ontruzant (SB3) a monoclonal antibody for treatment in breast cancer – was approved by European Medicines Agency (EMA).

Key Players

Major players operating in the global specialty injectable generics market include, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited , Sun Pharmaceutical Industries Limited, and Dr. Reddy's Laboratories.

Specialty injectable is a high cost drug therapy that requires administration by injection, inhalation or infusion. This medication is indicated in treatment of chronic or life threatening diseases such as HIV, rheumatoid arthritis, hemophilia, cancer, cardiovascular diseases, infectious diseases, auto immune disorders, and other diseases.

Market Dynamics

Increasing prevalence of chronic diseases such as cancer and cardiovascular diseases is a major factor driving the specialty injectable generics market growth. According to The National Cancer Institute, 2013, there are over 100 different types of cancers that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.

Moreover, expiration of the patents of majority of pharmaceutical and biotech products in the near future, especially in high value U.S. and Europe market is boosting the market growth.

However, stringent regulatory guidelines and low profit margins and drug shortage is expected to hamper growth of the global specialty injectable generics market. The shortages faced in the industry are primarily due to increased manufacturing issues, delay in supply, and shortage of Active Pharmaceutical Ingredients (API).

Key features of the study:

  • This report provides in-depth analysis of the specialty injectable generics market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global specialty injectable generics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited , Sun Pharmaceutical Industries Limited, and Dr. Reddy's Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
  • The global specialty injectable generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the specialty injectable generics market

Detailed Segmentation:

  • Global Specialty Injectable Generics Market, By Product Type:
    • Drugs
    • Biologics
  • Global Specialty Injectable Generics Market, By Application:
    • Oncology
    • Cardiovascular Diseases
    • Central Nervous System Diseases
    • Infectious Diseases
    • Auto-immune Disorders
    • Others
  • Global Specialty Injectable Generics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Specialty Injectable Generics Market, By Geography:
    • North America
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Drugs
        • Biologics
      • By Application:
        • Oncology
        • Cardiovascular Diseases
        • Central Nervous System Diseases
        • Infectious Diseases
        • Auto-immune Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Baxter International Inc.
    • Mylan N.V.
    • Fresenius SE & Co. KGaA
    • Endo International Plc
    • Hikma Pharmaceuticals PLC
    • Lupin Ltd.
    • Sagent Pharmaceuticals, Inc.
    • Cipla Limited
    • Sun Pharmaceutical Industries Limited
    • Dr. Reddy's Laboratories

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Specialty Injectable Generics Market, By Product Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Biologics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Specialty Injectable Generics Market, By Application, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Oncology
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Cardiovascular Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Central Nervous System Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Infectious Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Auto-immune Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Specialty Injectable Generics Market, By Distribution Channel, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global Specialty Injectable Generics Market, By Region, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France        
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      •  Pfizer, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Baxter International Inc.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Mylan N.V.
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius SE & Co. KGaA
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Endo International Plc
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Ltd.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sagent Pharmaceuticals, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Limited
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy's Laboratories
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 36 figures on “Specialty Injectable Generics Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.